HRP20100674T1 - Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka - Google Patents

Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka Download PDF

Info

Publication number
HRP20100674T1
HRP20100674T1 HR20100674T HRP20100674T HRP20100674T1 HR P20100674 T1 HRP20100674 T1 HR P20100674T1 HR 20100674 T HR20100674 T HR 20100674T HR P20100674 T HRP20100674 T HR P20100674T HR P20100674 T1 HRP20100674 T1 HR P20100674T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
preparation according
proportion
active agent
pharmaceutical
Prior art date
Application number
HR20100674T
Other languages
English (en)
Croatian (hr)
Inventor
Schckler Fritz
Wollenschl�ger Axel
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36507604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100674(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of HRP20100674T1 publication Critical patent/HRP20100674T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20100674T 2005-03-07 2010-12-06 Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka HRP20100674T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65882705P 2005-03-07 2005-03-07
PCT/EP2006/001574 WO2006094626A1 (en) 2005-03-07 2006-02-22 Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer

Publications (1)

Publication Number Publication Date
HRP20100674T1 true HRP20100674T1 (hr) 2011-01-31

Family

ID=36507604

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100674T HRP20100674T1 (hr) 2005-03-07 2010-12-06 Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka

Country Status (38)

Country Link
US (2) US9737488B2 (de)
EP (1) EP1868579B1 (de)
JP (1) JP5304241B2 (de)
KR (1) KR101335932B1 (de)
CN (2) CN104688697A (de)
AR (1) AR054234A1 (de)
AT (1) ATE482693T1 (de)
AU (1) AU2006222365B2 (de)
BR (1) BRPI0608840B8 (de)
CA (1) CA2601955C (de)
CR (1) CR9348A (de)
CU (1) CU23821A3 (de)
CY (1) CY1111065T1 (de)
DE (1) DE602006017188D1 (de)
DK (1) DK1868579T3 (de)
DO (1) DOP2006000057A (de)
ES (1) ES2351612T3 (de)
GT (1) GT200600096A (de)
HK (2) HK1118019A1 (de)
HN (1) HN2006009702A (de)
HR (1) HRP20100674T1 (de)
IL (1) IL185517A (de)
MA (1) MA29378B1 (de)
MX (1) MX2007010856A (de)
MY (1) MY162319A (de)
NO (1) NO343834B1 (de)
NZ (1) NZ561178A (de)
PE (1) PE20061345A1 (de)
PL (1) PL1868579T3 (de)
PT (1) PT1868579E (de)
SG (1) SG160364A1 (de)
SI (1) SI1868579T1 (de)
TN (1) TNSN07341A1 (de)
TW (1) TWI324928B (de)
UA (1) UA93673C2 (de)
UY (1) UY29410A1 (de)
WO (1) WO2006094626A1 (de)
ZA (1) ZA200707638B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
JP4777887B2 (ja) 2003-07-23 2011-09-21 バイエル、ファーマシューテイカルズ、コーポレイション 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
NZ553804A (en) * 2004-09-29 2010-07-30 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
EP1868579B1 (de) 2005-03-07 2010-09-29 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
US20090068146A1 (en) * 2005-10-31 2009-03-12 Scott Wilhelm Diaryl ureas and combinations
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル,リミティド ナノ粒子ソラフェニブ製剤
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US8680124B2 (en) 2007-01-19 2014-03-25 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
WO2009106825A1 (en) * 2008-02-27 2009-09-03 Cipla Limited Polymorphs of sorafenib and salts thereof
ES2969144T3 (es) 2008-05-15 2024-05-16 Celgene Corp Formulaciones orales de análogos de citidina y métodos de uso de los mismos
EP2440531A2 (de) * 2009-06-12 2012-04-18 Ratiopharm GmbH 4-[4-[[4-chlor-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridin-2-carboxamid-polymorphe
AU2011210326B2 (en) * 2010-01-29 2014-10-09 Sun Pharmaceutical Industries Limited Sorafenib dimethyl sulphoxide solvate
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
EP2559431A1 (de) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmazeutische Zusammensetzung umfassend 4-[4-[[4-Chlor-3-(trifluormethyl)phenyl]carbamoylamin]phenoxy]-N-methyl-pyridin-2-carboxamid
EP2806860B1 (de) 2012-01-23 2023-04-19 Sandoz AG Pharmazeutische zusammensetzung mit kristallin-sorafenib-tosylat
CA3015208C (en) 2012-06-04 2024-01-02 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
KR20170122220A (ko) 2015-03-03 2017-11-03 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나제 저해제의 약제학적 제제
WO2017159585A1 (ja) * 2016-03-14 2017-09-21 参天製薬株式会社 メグルミン又はその塩からなる防腐剤
CN106344530B (zh) * 2016-09-30 2019-03-19 京津冀联创药物研究(北京)有限公司 一种索拉非尼组合物及其制备方法
US11712418B2 (en) 2017-05-26 2023-08-01 Bruin Biosciences, Inc. Chemoembolization agents
US11179322B2 (en) 2018-07-10 2021-11-23 Novocure Gmbh Methods and compositions for treating tumors with TTFields and sorafenib
WO2018211336A2 (en) * 2018-09-07 2018-11-22 Alvogen Malta Operations (Row) Ltd Solid dosage form containing sorafenib tosylate
JP2022508055A (ja) 2018-11-01 2022-01-19 サイロス ファーマシューティカルズ, インコーポレイテッド サイクリン依存性キナーゼ7(cdk7)の阻害剤

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125359A (en) * 1964-03-17 Push-pull breakaway coupling
NL121140C (de) * 1961-11-08
AU594098B2 (en) 1985-12-11 1990-03-01 Ishihara Sangyo Kaisha Ltd. N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation
DK607188A (da) 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
US5773459A (en) 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
WO1997004765A1 (en) 1995-07-25 1997-02-13 Smithkline Beecham Corporation INHIBITION OF CoA-INDEPENDENT TRANSACYLASE AND APOPTOSIS
SK286662B6 (sk) 1996-04-23 2009-03-05 Vertex Pharmaceuticals Incorporated Deriváty močoviny, farmaceutické prostriedky, ktoré ich obsahujú, a ich použitie ako inhibítorov aktivity IMPDH enzýmu
JP2002500650A (ja) 1997-05-23 2002-01-08 バイエル、コーポレイション Rafキナーゼ阻害剤
WO1998052558A1 (en) 1997-05-23 1998-11-26 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
EP1041982B1 (de) 1997-12-22 2011-10-19 Bayer HealthCare LLC HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTE HETEROCYCLISCHE HARNSTOFFE
US20070244120A1 (en) * 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
UA67763C2 (uk) 1997-12-22 2004-07-15 Байер Фармасьютікалс Корпорейшн Арил- та гетероарилзаміщені гетероциклічні похідні сечовини, фармацевтична композиція та спосіб лікування захворювання, спричиненого кіназою raf
CN1213022C (zh) 1997-12-22 2005-08-03 拜尔有限公司 用对称和不对称的取代二苯脲抑制raf激酶
US7329670B1 (en) * 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
DE1042305T1 (de) 1997-12-22 2001-04-19 Bayer Ag HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN
TR200002618T2 (tr) 1997-12-22 2001-04-20 Bayer Corporation Sübstitüe edilmiş heterosiklik üreler kullanılarak raf kinazın inhibe edilmesi
JP2001526222A (ja) 1997-12-22 2001-12-18 バイエル コーポレイション アリールおよびヘテロアリール置換複素環尿素を使用するp38キナーゼ活性の阻害
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US20030087849A1 (en) 2001-07-03 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of HKR1 expression
US6117451A (en) 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
EP1140840B1 (de) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
ATE556713T1 (de) * 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
ME00275B (me) * 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
ES2281591T3 (es) * 1999-01-22 2007-10-01 Kirin Beer Kabushiki Kaisha Derivados de n-((quinolinil)oxil)-fenil)-urea y de n-((quinazolinil)oxil)-fenil)-urea con actividad antitumoral.
MXPA03001407A (es) * 2000-08-18 2003-06-06 Pharmacia Corp Formulacion oral de desintegracion rapida de un inhibidor de ciclooxigenasa-2.
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
TWI336328B (en) 2001-03-23 2011-01-21 Bayer Healthcare Llc Rho-kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20030207914A1 (en) * 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2002085857A2 (en) 2001-04-20 2002-10-31 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2003047579A1 (en) 2001-12-03 2003-06-12 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
AU2002365899B2 (en) * 2001-12-04 2007-09-13 Onyx Pharmaceuticals, Inc. RAF-MEK-ERK pathway inhibitors to treat cancer
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003068746A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
AU2003210969A1 (en) 2002-02-11 2003-09-04 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2003101444A1 (en) * 2002-05-29 2003-12-11 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
CA2516931C (en) 2003-02-28 2014-09-09 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
MXPA05009103A (es) 2003-02-28 2006-04-18 Bayer Pharmaceuticals Corp Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios.
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
JP4927533B2 (ja) 2003-02-28 2012-05-09 ニッポネックス インコーポレイテッド 癌その他の疾患の治療に有用な置換ピリジン誘導体
US6896863B2 (en) * 2003-04-01 2005-05-24 E. I. Du Pont De Nemours And Company Sodium cyanide process
PT1636585E (pt) * 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
US20060234931A1 (en) * 2003-07-17 2006-10-19 Biggs William H Iii Treatment of diseases with kinase inhibitors
WO2006125540A1 (en) 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
JP4777887B2 (ja) * 2003-07-23 2011-09-21 バイエル、ファーマシューテイカルズ、コーポレイション 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
JP2007505938A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Vegf受容体阻害剤と化学療法剤の組み合わせ
US7552093B2 (en) * 2003-12-04 2009-06-23 Black Duck Software, Inc. Resolving license dependencies for aggregations of legally-protectable content
WO2005059179A1 (en) 2003-12-12 2005-06-30 Bayer Pharmaceutical Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EP1751139B1 (de) 2004-04-30 2011-07-27 Bayer HealthCare LLC Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
BRPI0512567A (pt) 2004-06-22 2008-03-25 Pfizer Prod Inc compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
JP5128948B2 (ja) * 2004-08-27 2013-01-23 ニッポネックス インコーポレイテッド 癌の治療のための新規な薬剤組成物
CN101052619B (zh) 2004-09-29 2012-02-22 拜耳先灵制药股份公司 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]苯氧基}-n-甲基吡啶-2-甲酰胺的方法
NZ553804A (en) 2004-09-29 2010-07-30 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
EP1868579B1 (de) 2005-03-07 2010-09-29 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
US20090306020A1 (en) * 2005-05-27 2009-12-10 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
US20080305962A1 (en) 2005-07-29 2008-12-11 Ralph Markus Wirtz Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies
EP1946115A4 (de) 2005-10-21 2009-12-02 Bayer Healthcare Llc Verfahren zur vorhersage und prognose von krebs und überwachung der krebstherapie
US20090068146A1 (en) * 2005-10-31 2009-03-12 Scott Wilhelm Diaryl ureas and combinations
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
CA2627873A1 (en) * 2005-10-31 2007-05-10 Scott Wilhelm Treatment of cancer with sorafenib
KR20080077360A (ko) * 2005-11-02 2008-08-22 바이엘 헬스케어 엘엘씨 암의 예측 및 예후 방법, 및 암 치료 모니터링
WO2007056011A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
DE602006019468D1 (de) 2005-11-10 2011-02-17 Bayer Schering Pharma Ag Diarylharnstoffe zur behandlung von pulmonaler hypertonie
WO2007059155A1 (en) 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Treatment of cancers having resistance to chemotherapeutic agents
AU2006315592A1 (en) 2005-11-14 2007-05-24 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20100144749A1 (en) 2005-11-14 2010-06-10 Scott Wilhelm Treatment of cancers with acquired resistance to kit inhibitors
US20110195110A1 (en) 2005-12-01 2011-08-11 Roger Smith Urea compounds useful in the treatment of cancer
US20090227637A1 (en) * 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
JP2010514691A (ja) 2006-12-20 2010-05-06 バイエル ヘルスケア リミティド ライアビリティ カンパニー 4−{4−〔({3−tert−ブチル−1−〔3−(ヒドロキシメチル)フェニル〕−1H−ピラゾール−5−イル}カルバモイル)アミノ〕−3−フルオロフェノキシ}−N−メチルピリジン−2−カルボキサミド並びに癌の治療のためのそれのプロドラッグ及び塩
US8680124B2 (en) 2007-01-19 2014-03-25 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CA2840491A1 (en) 2011-06-28 2013-01-03 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sorafenib
EP2559431A1 (de) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmazeutische Zusammensetzung umfassend 4-[4-[[4-Chlor-3-(trifluormethyl)phenyl]carbamoylamin]phenoxy]-N-methyl-pyridin-2-carboxamid

Also Published As

Publication number Publication date
JP2008531741A (ja) 2008-08-14
US9737488B2 (en) 2017-08-22
EP1868579A1 (de) 2007-12-26
SI1868579T1 (sl) 2011-02-28
MA29378B1 (fr) 2008-04-01
HK1209620A1 (en) 2016-04-08
ES2351612T3 (es) 2011-02-08
NO20075042L (no) 2007-10-05
BRPI0608840A2 (pt) 2010-02-02
ZA200707638B (en) 2009-08-26
KR101335932B1 (ko) 2013-12-04
SG160364A1 (en) 2010-04-29
NZ561178A (en) 2010-11-26
DK1868579T3 (da) 2011-01-10
MX2007010856A (es) 2007-11-12
CA2601955C (en) 2012-07-10
HN2006009702A (es) 2010-06-08
BRPI0608840B8 (pt) 2021-05-25
HK1118019A1 (zh) 2009-01-30
EP1868579B1 (de) 2010-09-29
RU2007136896A (ru) 2009-04-20
CU20070203A7 (es) 2010-01-22
TW200700093A (en) 2007-01-01
WO2006094626A1 (en) 2006-09-14
AR054234A1 (es) 2007-06-13
US20080242707A1 (en) 2008-10-02
CR9348A (es) 2008-02-13
JP5304241B2 (ja) 2013-10-02
IL185517A (en) 2016-05-31
PT1868579E (pt) 2010-12-03
TWI324928B (en) 2010-05-21
CN101132779A (zh) 2008-02-27
BRPI0608840B1 (pt) 2020-04-14
AU2006222365B2 (en) 2011-07-14
CA2601955A1 (en) 2006-09-14
UY29410A1 (es) 2006-10-31
DE602006017188D1 (de) 2010-11-11
PL1868579T3 (pl) 2011-03-31
ATE482693T1 (de) 2010-10-15
PE20061345A1 (es) 2007-01-28
CN104688697A (zh) 2015-06-10
KR20070111513A (ko) 2007-11-21
AU2006222365A1 (en) 2006-09-14
IL185517A0 (en) 2008-01-06
UA93673C2 (ru) 2011-03-10
US20180036249A1 (en) 2018-02-08
CN101132779B (zh) 2016-03-16
TNSN07341A1 (en) 2008-12-31
CY1111065T1 (el) 2015-06-11
NO343834B1 (no) 2019-06-17
GT200600096A (es) 2007-01-12
DOP2006000057A (es) 2006-09-30
MY162319A (en) 2017-05-31
CU23821A3 (es) 2012-06-21
RU2420283C2 (ru) 2011-06-10

Similar Documents

Publication Publication Date Title
HRP20100674T1 (hr) Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka
JP2021038242A (ja) ルカパリブの高投与力価錠剤
US10064826B2 (en) Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
HRP20192064T1 (hr) Formulacije apiksabana
HRP20161262T1 (hr) Tablete ulipristal acetata
ITMI20001450A1 (it) Nuova composizione farmaceutica
ZA200508361B (en) Orally disintegrating tablets
JP2016536285A (ja) アムロジピン及びバルサルタンを含む安定な医薬組成物
JPS6241646B2 (de)
US20140335176A1 (en) Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing
JP6009967B2 (ja) 固形製剤
JP2017122056A (ja) 医薬含有造粒物の製造方法
JP2012529431A (ja) トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤
JP6308938B2 (ja) 粒状物を製造する方法
CN102349915A (zh) 一种氨酚咖敏维c制剂及其制备方法
JP2011246428A (ja) 口腔内崩壊型医薬品及びその製造方法
JP2007332074A (ja) 口腔内速崩壊錠およびその製造方法
JP2017520619A (ja) セリチニブ製剤
JP2004522780A5 (de)
HRP20191669T1 (hr) Farmaceutski sastav koji sadrži polimer koji veže fosfate
CA3122196A1 (en) Process for the preparation of easy-to-take tablets containing dry extract of ginkgo biloba leaves
CZ2007169A3 (cs) Farmaceutická kompozice s obsahem úcinné látky atorvastatinu
JP2005502729A (ja) 植物抽出物から錠剤を製造するための方法
CA3048968A1 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
ES2954286T3 (es) Composiciones de piridostigmina de liberación sostenida